Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of anquilisi (IMM-H012) in advanced solid tumors
CTR20253468Phase 2Active
- Sponsor
- Institute of Medical Biotechnology, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anquilisi in Nonhematologic neoplasms, colorectal cancer (CRC), gastric cancer (GC), bronchial carcinoma, breast cancer, sponsored by Institute of Medical Biotechnology, Chinese Academy of Medical Sciences. Started Sep 2025; status: active.
02
Drugs
anquilisi
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)gastric cancer (GC)bronchial carcinomabreast cancer
Beyond the preview
Go deeper on CTR20253468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253468.